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H I V
CD32 is expressed on cells with transcriptionally active 
HIV but does not enrich for HIV DNA in resting T cells
Mohamed Abdel-Mohsen,1* Leticia Kuri-Cervantes,2* Judith Grau-Exposito,3* Adam M. Spivak,4 
Racheal A. Nell,4 Costin Tomescu,1 Surya Kumari Vadrevu,1 Leila B. Giron,1 Carla Serra-Peinado,3  
Meritxell Genescà,3 Josep Castellví,5 Guoxin Wu,6 Perla M. Del Rio Estrada,7 Mauricio González-Navarro,7 
Kenneth Lynn,1,2,8 Colin T. King,9 Sai Vemula,6 Kara Cox,6 Yanmin Wan,10 Qingsheng Li,10 
Karam Mounzer,8 Jay Kostman,8 Ian Frank,2 Mirko Paiardini,9 Daria Hazuda,6 Gustavo Reyes-Terán,7 
Douglas Richman,11 Bonnie Howell,6 Pablo Tebas,2 Javier Martinez-Picado,12,13,14 Vicente Planelles,4 
Maria J. Buzon,3† Michael R. Betts,2† Luis J. Montaner1†
The persistence of HIV reservoirs, including latently infected, resting CD4+ T cells, is the major obstacle to cure HIV 
infection. CD32a expression was recently reported to mark CD4+ T cells harboring a replication-competent HIV 
reservoir during antiretroviral therapy (ART) suppression. We aimed to determine whether CD32 expression marks 
HIV latently or transcriptionally active infected CD4+ T cells. Using peripheral blood and lymphoid tissue of ART-treated 
HIV+ or SIV+ subjects, we found that most of the circulating memory CD32+ CD4+ T cells expressed markers of ac-
tivation, including CD69, HLA-DR, CD25, CD38, and Ki67, and bore a TH2 phenotype as defined by CXCR3, CCR4, 
and CCR6. CD32 expression did not selectively enrich for HIV- or SIV-infected CD4+ T cells in peripheral blood or 
lymphoid tissue; isolated CD32+ resting CD4+ T cells accounted for less than 3% of the total HIV DNA in CD4+ 
T cells. Cell-associated HIV DNA and RNA loads in CD4+ T cells positively correlated with the frequency of CD32+ 
CD69+ CD4+ T cells but not with CD32 expression on resting CD4+ T cells. Using RNA fluorescence in situ hybridization, 
CD32 coexpression with HIV RNA or p24 was detected after in vitro HIV infection (peripheral blood mononuclear 
cell and tissue) and in vivo within lymph node tissue from HIV-infected individuals. Together, these results indicate 
that CD32 is not a marker of resting CD4+ T cells or of enriched HIV DNA–positive cells after ART; rather, CD32 is pre-
dominately expressed on a subset of activated CD4+ T cells enriched for transcriptionally active HIV after long-term ART.
INTRODUCTION
The main barrier to HIV eradication is the ability of HIV-1 to establish 
latency in long-lived resting CD4+ T cells (1, 2), which persist in blood 
and tissues (3–6). Quiescent CD4+ T cells harboring latent HIV do 
not produce virus until they are activated to produce infectious virus 
(7–14). These latently infected cells are likely the source of rebound 
after interruption of antiretroviral therapy (ART), and their continual 
reactivation in vivo probably contributes to ongoing immune activa-
tion, inflammation, and organ damage that persists even under sup-
pressive ART (15–23).
Despite nearly two decades of research, it remains unclear what 
mechanisms govern latency in vivo and persistence of HIV after 
therapy. One major obstacle to progress is the inability to distinguish 
and identify latently infected cells in vivo, which has precluded a full 
understanding of HIV latency and hampered the development of 
curative strategies. Because latently infected cells express little or no 
HIV RNA or protein, strategies for eliminating HIV latency will likely 
require identification of host factors that can be used to identify and 
target latently infected cells.
Recently, Descours et al. (24) suggested that CD32a (FcRIIa), an 
Fc receptor mainly expressed on myeloid cells and platelets, is a 
potential biomarker of the CD4+ T cell HIV reservoir harboring 
replication-competent proviruses in ART-suppressed individuals. 
However, because this report did not exclusively define resting versus 
activated CD4+ T cells, it remains unclear whether CD32a is specif-
ically enriched in resting latently infected CD4+ T cells. Previous 
studies have demonstrated that CD32 is rarely expressed by rest-
ing CD4+ T cells (25, 26) compared to activated T cells (27–29), fur-
ther stressing the need to characterize CD32 expression on resting 
CD4+ T cells in HIV-infected individuals. To address this issue, we 
examined whether CD32 is associated with resting or activated CD4+ 
T cells in ART-treated individuals, whether CD32 expression can 
enrich for HIV DNA copies in total or resting CD4+ T cells, and 
whether it aligns with latent or transcriptionally active HIV-infected 
CD4+ T cells.
RESULTS
CD32+ CD4+ T cells are enriched with activated cells rather 
than with resting cells
HIV latency has been functionally defined in resting CD4+ lymphocytes 
(CD4+, CD69−, CD25−, and HLA-DR−), which lack expression of 
virions or viral antigens (7, 30–35). We measured CD4+ T cell surface 
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expression of CD32 and activation markers [CD69 for early activation, 
CD25 for intermediate or late activation, and human leukocyte 
antigen–DR (HLA-DR) for late activation] using flow cytometry on 
fresh blood from ART-suppressed HIV-infected individuals with 
<50 copies/ml of plasma viral load (VL), HIV-infected individuals 
with VL >50 copies/ml, and HIV− controls (table S1). We also as-
sessed the expression of CD32 on cryopreserved peripheral blood 
mononuclear cells (PBMCs) from ART-suppressed HIV- infected 
individuals. CD32 was detected on the surface of CD4+ T cells from 
(i) HIV− controls [median, 5.7%; interquartile range (IQR), 4.1%], 
(ii) HIV+ individuals with VL <50 copies/ml (median, 4%; IQR, 1.95%), 
and (iii) HIV+ individuals with VL >50 copies/ml (median, 3.1%; 
IQR, 3%) (Fig. 1A). The frequency of CD32 on fresh CD4+ T cells in 
ART- suppressed HIV+ individuals (median, 4%; IQR, 1.95%) was sig-
nificantly higher (P < 0.0001) than that on frozen cells (median, 0.41%; 
IQR, 0.3%) (Fig. 1B). Despite the frequency difference, there was no 
phenotypic difference between CD32+ CD4+ T cells from fresh and 
frozen samples. Following the gating strategy used by Descours et al. 
(24), we divided CD32+ CD4+ T cells into cells expressing intermedi-
ate levels of CD32 (CD32intermediate) and cells expressing high lev-
els of CD32 (CD32hi) (fig. S1). CD32intermediate was detected on the 
surface of CD4+ T cells from (i) HIV− controls (median, 5.0%; IQR, 
4.2%), (ii) HIV+ individuals with VL <50 copies/ml (median, 3.9%; 
IQR 1.97%), and (iii) HIV+ individuals with VL >50 copies/ml (me-
dian, 2.9%; IQR, 3%) (Fig. 1C). CD32hi was detected on the surface 
of CD4+ T cells from (i) HIV− individuals (median, 0.26%; IQR, 0.16%), 
(ii) HIV+ individuals with VL <50 copies/ml (median, 0.16%; IQR, 0.14%), 
and (iii) HIV+ individuals with VL >50 copies/ml (median, 0.16%; 
IQR, 0.06%) (Fig. 1D).
A higher proportion of CD32+ CD4+ T cells expressed the acti-
vation markers CD69, HLA-DR, or CD25 compared to CD32− CD4+ 
T cells (P = 0.03 in HIV− individuals, P < 0.0001 in HIV+ individuals 
Fig. 1. CD32+ CD4+ T cells are enriched with activated cells. Freshly isolated peripheral blood mononuclear cells (PBMCs) from HIV− controls, HIV+ individuals with 
VL <50 copies (cp)/ml, and HIV+ individuals with VL >50 copies/ml were stained for CD32, CD69, HLA-DR, and CD25 on CD4+ T cells. (A) Percentage of total CD32+ within 
CD4+ T cells. (B) Percentage of total CD32+ CD4+ T cells in cryopreserved PBMCs from HIV+ individuals with VL <50 copies/ml. (C) Percentage of CD32intermediate within 
CD4+ T cells. (D) Percentage of total CD32hi within CD4+ T cells. (E) Percentage of cells expressing at least one of the activation markers human leukocyte antigen–DR 
(HLA-DR), CD69, and CD25 on CD32+ CD4+ T cells and CD32− CD4+ T cells. Lines and error bars represent median and IQR, respectively. All statistical comparisons were 
performed using two-tailed Wilcoxon rank tests. n = 6 for HIV− controls, n = 27 for HIV+ ART+ (<50 copies/ml) individuals, and n = 7 for HIV+ (>50 copies/ml) individuals. 
*P < 0.05 and ****P < 0.0001.
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with VL <50 copies/ml, and P = 0.016 in HIV+ individuals with VL 
>50 copies/ml). The frequency of CD32+ CD4+ T cells expressing 
one or more of the three activation markers (median, 43.9%; IQR, 
33%) was higher compared to CD32− CD4+ T cells (median, 12.3%; 
IQR, 7.8%) in HIV+ ART-suppressed individuals (P < 0.0001) (Fig. 1E). 
The percentages of CD69+, HLA-DR+, or CD25+ as measured indi-
vidually were also significantly higher on CD32+ cells compared to 
CD32− cells (fig. S2). These data indicate that activated rather than 
resting CD4+ T cells are enriched within CD32+ CD4+ cells.
CD32+ memory CD4+ T cells have a TH2 phenotype and 
express activation markers
We next examined the composition and distribution of CD32 
expression in CD4+ T cell subpopulations from PBMC samples of 
uninfected, ART-suppressed, and untreated viremic HIV-infected 
donors analyzed by two independent laboratories in Philadelphia and 
Barcelona (table S3). Flow cytometry gating strategies used for the 
identification of CD4+ T cell subsets and CD32 expression are shown 
in fig. S3. We found that the overall distribution of CD32+ HLA- 
DR− CD4+ T cells between HIV− and HIV-infected individuals was 
similar, irrespective of the presence of viremia (Fig. 2A). We next 
focused on the distribution of CD32+ HLA-DR− CD4+ T cells 
among the different memory CD4+ T cell subsets. We observed 
that most CD32+ cells had either a naïve or a central memory T cell 
(TCM) phenotype (median percentages/IQR for naïve, 53.2/6.6 
in HIV−Philadelphia, 53.3/19.1 in HIV-infected ART+Barcelona, and 
40.9/18.1 in HIV-infected ART+Philadelphia; median percentages/IQR 
for TCM, 25.3/9.2 in the HIV−Philadelphia and 34.9/10.5 in HIV- infected 
ART+Philadelphia). Overall, naïve and TCM CD4+ T cells harbored 
more than 90% of all CD32+ cells found in peripheral blood. We did 
not observe any significant differences between viremic and ART- 
treated subjects.
We further characterized the T helper cell (TH) phenotype of 
CD32-expressing memory CD4+ T cells within HIV-infected indi-
viduals from the cohort analyzed in Philadelphia. To identify the TH 
phenotype, we analyzed the frequency of follicular helper T cells 
(Tfh; CXCR5+ PD1+), regulatory T cells (Tregs; CD127lo/− CD25+), 
TH1 (CXCR3+ CCR4− CCR6−), TH2 (CXCR3− CCR4+ CCR6−), and 
TH17 (CXCR3− CCR4− CCR6+) within total memory CD32+ CD4+ 
T cells (Fig. 2B). Most cells remained undefined, but in those CD32+ 
cells for which we could identify defined TH subsets, we observed 
that the frequency of TH2 cells was significantly higher than all others 
(P < 0.05 for all cases). However, we observed that this enrichment 
was only found in CD32+ HLA-DR+ cells and CD32− HLA-DR+ 
cells, but not in CD32+ HLA-DR− cells. These data suggest that 
activation, rather than CD32+ expression, skewed the differentiation 
into TH2 in this cohort.
We further found that most memory CD32+ CD4+ T cells ex-
pressed one or more activation markers (Fig. 2, C and D), independent 
of HLA-DR alone. Whereas HLA-DR+ cells generally expressed other 
activation markers, CD32+ HLA-DR− cells showed similarly high ac-
tivation profiles, including significantly higher frequencies of CD38+ 
(P < 0.0001) and Ki67+ (P < 0.0001) cells, compared to CD32− cells. 
We also observed that memory CD32+ CD4+ T cells had lower fre-
quencies of programmed cell death protein 1 (PD-1) and CD57 when 
compared with memory CD32− cells (P = 0.017 and P < 0.0001, re-
spectively). Of note, CD32+ naïve CD4+ T cells also had higher fre-
quencies of activation markers compared to CD32− cells (P = 0.035 
for HLA-DR, P = 0.0005 for CD38, and P < 0.0001 for Ki67).
Finally, we incorporated the analyzed parameters within memory 
CD32+ and CD32− CD4+ T cells and performed unbiased clustering 
and principal components analyses (PCAs) of the entire data set 
(Fig. 2, E and F). These analyses confirmed that CD32+ cells have a 
phenotype distinctive from CD32− cells, and this phenotype is sim-
ilar between viremic and aviremic HIV+ individuals.
CD32+ cells are similar between blood and tonsils  
of ART-treated HIV+ donors
Given the central importance of lymphoid tissues as a source of the 
HIV reservoir during HIV/simian immunodeficiency virus (SIV) in-
fection (3–6), we investigated the frequency of expression of CD32+ 
CD4+ T cells, subset distribution, and phenotype in tonsil samples 
from ART-treated HIV-infected individuals from the Philadelphia 
cohort (Fig. 3 and fig. S4). We first compared frequencies of CD32+ 
cells in four paired PBMC and tonsil samples. We found a higher 
frequency of CD32+ HLA-DR+ CD4+ T cells in tonsils when com-
pared to blood (median percentages/IQR, 27.7/4.3 and 10.11/11.29, 
respectively), but this proportion was inverted in CD32− HLA-DR− 
CD4+ T cells (median percentages/IQR, 89.9/11.3 in blood and 
72.3/4.3 in tonsils). These differences did not reach statistical signif-
icance, possibly because of the low sample number (P > 0.05 for all 
cases; fig. S4, A to C). We first analyzed the distribution of CD32+ 
HLA-DR− CD4+ T cells in memory subsets in tonsils, and similar to 
our observation in blood (Fig. 2), TCM was the most frequent memory 
subset (median, 52.8%; IQR, 24.9%; Fig. 3A). In contrast to our find-
ings in blood (Fig. 2), we did not see an enrichment of naïve cells 
within CD32+ HLA-DR− CD4+ T cells.
We also characterized the proportions of CD32- and HLA-DR–
expressing cells within CD4+ T cell subsets (fig. S4D). In contrast with 
periphery, TCM and terminally differentiated memory cells (TTD) 
had the highest frequency of CD32+ HLA-DR− CD4+ T cells in the 
analyzed tonsils (median percentages/IQR, 0.30/0.34 and 0.36/0.78, 
respectively). Overall, we observed a similar distribution of CD32+ 
cells and enrichment of CD32/HLA-DR–expressing cells within CD4+ 
T cells in tonsils, as we found in blood.
When focusing our analysis on memory CD4+ T cells, we found 
that the most frequent definable profile within CD32+ cells was TH2, 
in agreement with our findings in blood, and TH17 (median percentages/
IQR, 21.5/14.4 in TH2 and 14.8/3.7 in TH17; Fig. 3B). Similar to our 
findings in PBMCs, we found that tonsillar CD32+ memory CD4+ 
T cells have higher frequencies of CD38+ and Ki67+ cells than their 
CD32− counterparts (Fig. 3, C and D). Furthermore, CD32+ and CD32− 
memory CD4+ T cells show different phenotypic profiles (Fig. 3E). We 
further confirmed this enrichment in the frequency of CD32+ CD4+ 
T cells, compared to CD32− CD4+ T cells, expressing HLA-DR and Ki67 
in blood and lymph node (LN) cells isolated from five ART-suppressed, 
SIV-infected rhesus macaques (RMs; fig. S5). Overall, these data 
dem onstrate that the frequency and phenotype of CD32+ cells in lym-
phoid tissues analyzed largely parallel those in the peripheral blood.
CD32 expression associates with productive HIV infection  
in vitro and ex vivo
To investigate the direct effect of HIV replication on CD32 expression, 
ex vivo infection kinetics were examined using unstimulated PBMCs 
from three healthy donors. Cells were infected for up to 6 days and 
subjected to the RNA fluorescence in situ hybridization (FISH)–
flow assay for the assessment of CD32, HLA-DR, and PD-1 expression on 
HIV-infected cells. Productively HIV- infected cells were defined 
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Fig. 2. CD32+ cells have a distinctively different phenotype compared to CD32− cells. (A) Distribution of CD32+ HLA-DR− within cell subsets in viremic, ART-treated HIV + 
and HIV− donors. In the Barcelona cohort, subsets were defined as naïve (CD45RO− CD27+), TTD (CD45RO− CD27−), effector memory T cells (TEM) (CD45RO+ CD27−), and central 
memory T cells (TCM)/transitional memory T cells (TTM) (CD45RO+ CD27+). In the Philadelphia cohort, subsets were defined as naïve (CD45RA+ CD27+ CCR7+ CD95−), stem memory 
T cells (TSCM) (CD45RA+ CD27+ CCR7+ CD95+), TTD (CD45RA+ CD27−), TEM (CD45RA− CD27−), TCM (CD45RA− CD27+ CCR7+), and TTM (CD45RA− CD27+ CCR7−). (B) Frequencies of 
TH subsets within memory CD32+ CD4+ T cells (top) and their distribution within HLA-DR+/− TH2 CD32+ CD4+ T cells (bottom). Not subset refers to those cells that did not 
fall into the defined TH subsets. (C and D) Frequency of CD38+ (C) and Ki67+ (D) cells in CD32/HLA-DR–expressing memory CD4+ T cells. Representative examples are shown for 
each marker with overlaid plots showing CD32+ cells (red dots in plots and solid red lines in histograms) over total memory cells (black dots in plots and dotted lines in histograms). 
(E) Heat map showing the frequency of all measured phenotypic markers in CD32+ and CD32− cells. CD32p, memory CD32+ CD4+ T cells; CD32n, memory CD32− CD4+ T cells. 
(F) PCA showing the distribution of CD32+ and CD32− cell subsets. In all graphs, a line indicates the median of the group. All data were analyzed using a Friedman test (paired, 
nonparametric) and corrected for multiple comparisons with Dunnett’s posttest. n = 6 for HIV − controls, n = 12 for HIV + ART + individuals, and n = 8 for HIV+ viremic individuals. 
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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as cells coexpressing HIV RNA and the p24 
viral protein (Fig. 4A). At day 3 after infection, 
we found that a median of 11% of infected 
cells expressed CD32 compared to uninfected 
cells, present in the same culture, in which 
fewer cells were expressing CD32 (median, 
0.45%; Fig. 4B). This percentage of CD32 was 
longitudinally stable on HIV-infected cells. 
Moreover, a direct positive correlation was 
found between the percentage of HIV-infected 
cells and the intensity of CD32 expression on 
these infected cells, possibly suggesting that 
a portion of actively transcribing HIV-infected 
cells express CD32 after cell infection (Fig. 4B, 
right). We next investigated the expression of 
HLA-DR and PD-1 on productively infected 
cells coexpressing CD32 (Fig. 4C). Infected cells 
had a higher proportion of HLA-DR+ cells, 
and this frequency was higher in CD32+ cells 
when compared to CD32− cells (mean, 85.5 and 
51.6% for CD32+ and CD32− infected cells, 
respectively, at day 3 after infection). Simi-
lar results were obtained for PD-1 expression: 
We found a mean frequency of 27.6% PD-1+ 
CD32+ cells versus 14.8% PD-1+ CD32− infected 
cells after 3 days of infection (Fig. 4C). Of note, 
uninfected cells expressed very low frequencies 
of both HLA-DR and PD-1 (1.8 and 1.1%, 
respectively). Given that CD32 expression has 
been shown to increase after in vitro poly-
clonal activation (36), we then focused on HIV 
infection of previously activated CD4+ T cells. 
We observed an increase of CD32 in un-
infected CD4+ T cells after 72-hour exposure 
to anti-CD3/CD28 antibodies compared to 
controls (P = 0.007; n = 8). As with nonac-
tivated cells, we also found that HIVNL4–3 in-
fection of activated cells further up-regulates 
the frequency of CD32+ cells (Fig. 4D).
Using an ex vivo tissue model of HIV 
infection, cervical tissues from two HIV− 
patients were infected with HIVBal virus. Twelve 
days after infection, cells were analyzed by 
flow cytometry to characterize the frequency 
of infected cells and their coexpression of CD32 
and HLA-DR. HIV- infected cells showed 
larger proportions of CD32+ cells than un-
infected CD4+ T cells (median, 18.2 and 5.9% 
for infected and uninfected cells, respectively) 
(Fig. 4E). Infected CD32+ cells also had higher 
frequencies of HLA-DR+ cells compared to 
CD32− CD4+ T cells (median, 38.1 and 16.5% 
for infected CD32+ and CD32−, respectively) 
(Fig. 4F). Overall, after ex vivo infection of 
unstimulated PBMCs and cervical tissue, 
~15% of infected cells expressed the CD32 
marker, and this pop ulation had higher HLA- 
DR and PD-1 frequencies than their CD32− 
counterparts.
Fig. 3. Frequency and distribution of CD32+ 
cells are similar between blood and tonsils of 
ART-treated HIV+ donors. (A) Distribution of 
CD32+ HLA-DR− within cell subsets in tonsil sam-
ples from ART-treated HIV+ donors. (B) Frequencies 
of TH subsets within memory CD32+ CD4+ T cells. 
Not subset refers to those cells that did not fall 
into the defined TH subsets. (C and D) Frequency 
of CD38+ (C) and Ki67+ (D) cells in CD32/HLA-
DR–expressing memory CD4+ T cells. Represen-
tative examples are shown for each marker with 
overlaid plots showing CD32+ cells (red dots in 
plots and solid red lines in histograms) over total 
memory cells (black dots in plots and dotted lines 
in histograms). (E) Heat map showing the frequency 
of all measured phenotypic markers in CD32+ and 
CD32− cells. In all graphs, a line indicates the me-
dian of the group. All data were analyzed using a 
Friedman test (paired, nonparametric) and cor-
rected for multiple comparisons with Dunnett’s 
posttest. *P < 0.05; n = 4.
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CD32+ CD4+ T cells from ART-suppressed HIV-infected 
patients show no enrichment of HIV DNA, and CD32+ resting 
and activated CD4+ T cells contribute minimally to the total 
pool of HIV DNA in CD4+ T cells
To investigate the possible role of CD32 expression for identifying 
the HIV reservoir in vivo, measurements of HIV DNA were per-
formed on CD32 pull-downs with anti-CD32 antibody–conjugated 
magnetic beads (with PBMCs from HIV+ ART-suppressed individ-
uals) and compared to preimmunoprecipitation pull-downs nor-
malized for cell numbers. We did not detect any enrichment of HIV 
DNA in CD4+ CD32+ pull-downs relative to controls (Fig. 5A). In 
addition, we used anti-CD32 antibody–conjugated magnetic beads 
Fig. 4. CD32 expression as-
sociates with productive HIV 
infection in vitro in PBMCs 
and tissues. Unfractionated 
and unstimulated PBMCs from 
three healthy donors were in-
fected ex vivo with the HIV strain 
NL4-3. Cells were subjected to 
the RNA FISH–flow protocol on 
days 3, 4, 5, and 6 after infection 
to de termine the expression of 
CD32 in the productively in-
fected cell population (HIV-RNA+ 
p24+). (A) Left: A representative 
flow cytometry plot of dually 
stained T cells for HIV RNA and 
the p24 protein. Upper right pan-
els show representative flow cy-
tometry plots of CD32, HLA-DR, 
and PD-1 frequency and expres-
sion in uninfected cells. The plots 
in the middle and bottom right 
show the frequency and expres-
sion of CD32 in infected cells 
and the frequency of HLA-DR 
and PD-1 within infected CD32+ 
cells at days 3 and 6 after infec-
tion. (B) Percentages of pro-
ductively HIV- infected cells 
(first graph) and percentages of 
infected cells expressing CD32 
(second graph). MFI of p24 and 
CD32 expression productive-
ly infected (orange) and unin-
fected cells (blue) (third and 
fourth graphs). Correlation be-
tween the percentage of HIV- 
infected cells and CD32 expres-
sion (last graph). (C) Differential 
HLA-DR and PD-1 expression pat-
tern of infected cells (green), 
cells coexpressing the CD32 
marker (maroon), or uninfected 
cells (blue). Left graph shows the expression of the activation marker 
HLA-DR, and right graph shows the expression of PD-1. (D) Left graph: 
Percentages of CD32 expression in uninfected cells after exogenous 
stimulation with anti-CD3/CD28 microbeads. Middle graph: Percentages 
of HIV- infected cells after ex vivo infection of stimulated CD4+ T cells. 
Right graph: Percentages of CD32 expression after ex vivo infection 
of stimulated CD4+ T cells. (E) Cervical tissue ex vivo infection. Left graph: 
Representative flow cytometry plot of p24 protein detection in two 
cervical tissues after 12 days of HIV infection. Right graph: Detection 
of CD32 in HIV-infected cells and in uninfected CD4+ T cells. (F) Percentages of HLA-DR 
expression in infected cells expressing the CD32 marker (maroon), infected cells that 
do not express CD32 (green), and uninfected CD4+ T cells expressing CD32 (blue). Sta-
tistical comparisons were performed using paired t tests. n = 2.
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to isolate CD32+ resting CD4+ T cells 
(HLA-DR− CD69− CD25−) and CD32− 
resting CD4+ T cells from PBMCs of 
HIV+ ART-suppressed individuals. No 
enrichment of HIV DNA was observed 
in CD32+ resting CD4+ T cells when com-
pared to CD32− resting CD4+ T cells 
(Fig. 5B). Finally, we measured HIV DNA 
in CD4+ T cells FACS (fluorescence- 
activated cell sorting)–sorted based on 
activation status and CD32 expression 
as shown in Fig. 5C. All sorted popula-
tions were isolated within 2 hours of 
collection of blood from HIV+ ART- 
suppressed individuals (Fig. 5C and 
table S2). No enrichment of HIV DNA 
load was observed between all compared 
populations. In addition, the contribu-
tion of CD32+ CD4+ T cells to the total 
pool of HIV DNA in CD4+ T cells was 
significantly lower than that of CD32− CD4+ T cells (Fig. 5, D and 
E). Our data show that CD32− resting CD4+ T cells contribute the 
most (median, 75.86%) to the total pool of HIV DNA in total CD4+ 
T cells, followed by CD32− activated CD4+ T cells (median, 18.1%), 
CD32+ activated CD4+ T cells (median, 4.7%), and, last, CD32+ 
resting CD4+ T cells (median, 2.2%). Similar analyses were per-
formed on CD32+ versus CD32− CD4+ T cells isolated from the LNs 
of the five ART-suppressed SIV-infected RMs described above. No 
Fig. 5. No enrichment of HIV DNA in sorted 
CD32+ CD4+ T cells compared to CD32− CD4+ 
T cells and CD32+ resting CD4+ T cells contribute 
minimally to the total pool of HIV DNA in CD4+ 
T cells. (A) Measurements of HIV DNA were per-
formed on CD32 pull-downs with antibody- 
conjugated magnetic beads and compared to cell 
number normalized pre-immunoprecipitation 
(pre-IP) pull-downs (n = 7) on fresh cells. (B) HIV 
DNA load was measured from CD32+ resting CD4+ 
T cells and CD32− resting CD4+ T cells isolated using 
magnetic beads (n = 6). (C) FACS was performed to 
isolate total CD4+ T cells, CD32+ CD4+ T cells, CD32− 
CD4+ T cells, CD32− resting CD4+ T cells (HLA-DR− 
CD69− CD25−), CD32+ resting CD4+ T cells, CD32− acti-
vated CD4+ T cells (HLA-DR+ or CD69+ or CD25+), 
and CD32+ activated CD4+ T cells from freshly iso-
lated PBMCs from HIV+ ART-suppressed individ-
uals, and HIV DNA load was measured in all sorted 
populations (n = 10). Each patient is represented 
by a different symbol. Lines represent median. 
(D and E) Contribution of each cell population to the 
total pool of HIV DNA in CD4+ T cells calculated 
in 10 HIV+ ART-suppressed individuals. HIV total 
DNA copy number was determined in sorted sub-
sets by qPCR. Each symbol represents a different 
individual. The contribution of each subset to the 
total pool of HIV DNA in CD4+ T cells was calcu-
lated by accounting for the frequency of these sub-
sets within the CD4+ compartment and abundance 
of HIV DNA determined in each subset. Horizon-
tal lines indicate median values. All statistical 
comparisons were performed using two-tailed 
Wilcoxon rank tests. *P < 0.05 and **P < 0.01.
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enrichment of SIV DNA was detected in CD32+ CD4+ T cells when 
compared to CD32− CD4+ T cells in the LNs of ART-suppressed, 
SIV-infected RMs (fig. S5).
CD32 on CD69+ but not on resting CD4+ T cells enriches for 
HIV DNA and RNA in peripheral blood from ART-suppressed 
HIV-infected patients
The frequency of CD32+ cells on total or resting CD4+ T cells was 
not associated with total HIV DNA load measured by quantitative 
polymerase chain reaction (qPCR) [Fig. 6 (A and B) and fig. S6 (A 
to D)]; however, the frequency of CD32+ CD69+ CD4+ T cells ex-
hibited a moderate significant correlation with total HIV DNA load 
in isolated CD4+ T cells from HIV+ ART-suppressed individuals 
(rho = 0.44, P = 0.036) (Fig. 6, C and D). Because CD32+ cells are 
enriched in activated cells that are likely transcriptionally active, we 
sought to examine a possible correlation between CD32 expression 
and cell-associated HIV RNA load as a marker of HIV transcription 
in PBMC from HIV+ ART-suppressed individuals. Cell-associated 
HIV RNA load correlated positively with the frequency of CD32+ 
CD69+ CD4+ T cells as measured in PBMCs (rho = 0.48, P = 0.0099) 
or in isolated CD4+ T cells (rho = 0.66, P = 0.0002), but not with 
frequencies of CD32+ on total CD4+ T cells (Fig. 6, E to H), or resting 
CD4+ T cells (fig. S6, E and F). Whereas CD32 and CD69 expression 
showed the highest association with cell-associated HIV RNA load, 
CD69 expression in CD32− CD4+ T cells also showed a lower but 
significant correlation with cell-associated HIV RNA load measured 
in unfractionated PBMCs (rho = 0.4, P = 0.04) and isolated CD4+ 
T cells (rho = 0.53, P = 0.004) (fig. S7), indicating that not all circulat-
ing CD4+ T cells that are HIV transcriptionally active express CD32. 
However, as shown in fig. S6 (K to R), total activated (CD69+ or 
HLDR+ or CD25+) CD32− or resting CD4+ T cells did not show 
significant associations with cell-associated HIV RNA load.
CD32 expression associates with HIV-RNA in LNs  
of HIV-infected patients
To better understand the relationship between HIV RNA and CD32a 
expression, we visualized and quantified HIV RNA and CD32a 
RNA in anatomically intact LN tissue from viremic and ART-treated 
HIV-infected patients, and HIV− controls. HIV RNA and CD32a 
RNA were detected in paraffin-embedded tissue samples. As shown 
in Fig. 7A, we observed two HIV RNA expression patterns: (i) pro-
ductively HIV-infected cells that typically have a densely staining 
spherical signal that involves the entire cell and (ii) small punctate 
structures with a diffuse lattice-like signal pattern compatible with 
the capture of HIV virions by follicular dendritic cells in B cell folli-
cles, as reported previously (37). Of note, we did not perform the 
phenotypic identification of transcriptionally active infected cells in 
LNs, but reports have shown that productively HIV-infected cells 
align with CD45RO+ memory CD4+ T cells (38). Using a specific set 
of RNA probes, we evaluated CD32a expression. The observed stain-
ing and localization of CD32a were compatible with the presence of 
subcapsular sinus macrophages in LNs. In addition, in the analyzed 
six HIV-infected patients, a high percentage of HIV-expressing cells 
localized within the B cell follicle also coexpressed the CD32a tran-
scripts (median, 94%) compared to 4% of cells that were single CD32a+ 
and 2% of cells that only expressed HIV RNA. The B cell follicle has 
been identified as an immune-privileged sanctuary site for HIV 
persistence (39). No differences were observed between viremic and 
aviremic donors (Fig. 7B). After inspecting a median of 74 B cell 
follicles per donor, CD32a single-positive cells were detected at a 
median frequency of 6.3% in viremic and 1.7% in ART-treated pa-
tients. Cells coexpressing the CD32a receptor and HIV RNA were 
detected at a median frequency of 94.3% in viremic and 60.2% in 
ART- treated patients (Fig. 7C and fig. S8). Of note, CD32a was 
highly up-regulated in HIV RNA–positive HIV-infected cells. The 
Fig. 6. Frequency of CD32+ on CD69+ cells correlates with HIV DNA and RNA loads during suppressive ART. (A to D) Frequency of CD32+ CD4+ T cells and frequency 
of CD32+ on CD69+ CD4+ T cells were examined in relation to total HIV DNA load measured in unfractionated PBMCs and isolated CD4+ T cells. (E to H) Frequency of CD32+ 
CD4+ T cells and frequency of CD32+ on CD69+ CD4+ T cells were examined in relation to cell-associated HIV RNA load measured in unfractionated PBMCs and isolated 
CD4+ T cells. Correlations were evaluated using two-tailed Spearman’s rank correlation coefficient tests. n = 27 HIV+ ART+ individuals.
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Fig. 7. CD32 expression associates with HIV-RNA. 
(A) Paraffin-embedded sections from HIV-infected 
patients and a healthy donor LN biopsy were stained 
for HIV-1 RNA (red), CD32a RNA (green), and nuclei 
(blue). Upper panel shows a representative section 
of an HIV− donor, and a viremic HIV-infected pa-
tient is shown in lower panels. White arrows indicate 
cells coexpressing HIV and CD32a. Lower panels 
show high magnification of one cell coexpressing 
HIV and CD32a from a viremic HIV-infected patient. 
(B and C) Quantification of single HIV-1 RNA–, single 
CD32a RNA–, and double HIV-1 RNA– and CD32a 
RNA–positive cells in B cell follicles of LNs from four 
HIV-infected viremic patients, and two HIV-infected 
patients with undetectable viral load. Results are rep-
resented (B) as a percentage of the total HIV RNA–
positive cells and/or CD32a RNA–positive cells with-
in B cell follicles or (C) as the total number of cells 
per 102 inspected B cells follicles. (D) Spearman cor-
relation between the MFI of CD32 RNA expression 
and the MFI of HIV-1 RNA expression. The same four 
viremic HIV-positive patients used in (B) and (C) are 
shown. n = 6. A.U., arbitrary units.
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expression for both RNAs, HIV and CD32a [defined by the mean 
fluorescence intensity (MFI)], was highly correlated in all analyzed 
patients (Fig. 7D). Overall, in LNs of HIV-infected patients, most of 
the cells expressing HIV RNA also coexpress the CD32a receptor, 
whereas CD32a single-positive cells within the B cell follicle were 
rarely observed.
DISCUSSION
We report that CD32 expression in CD4+ T cells is a marker for a 
subset of activated CD4+ T cells containing HIV transcripts after 
ART-mediated suppression. We find no evidence to support that 
CD32 expression favors resting CD4+ T cells or enriches for HIV 
DNA copy number in sorted resting CD4+ T cells commonly used 
to measure the latent HIV reservoir. We found evidence that CD32 
expression favors activated CD4+ T cells and is coexpressed with HIV 
RNA in infected cells in vitro and in vivo.
Our data showing no enrichment of HIV DNA in CD32+ CD4+ 
cells do not confirm the data in the recent report by Descours et al. (24) 
that CD32+ CD4+ T cells contribute 26.8 to 83.3% to the total pool of 
HIV DNA in CD4+ T cells. Our data show that CD32− resting CD4+ 
T cells contribute the most to the total pool of HIV DNA in total 
CD4+ T cells (~76%), whereas CD32+ CD4+ T cells, activated or rest-
ing, contribute minimally to this pool (4.7 and 2.2%, respectively). 
These results challenge the notion that CD32 enriches for HIV la-
tently infected cells as suggested by Descours et al. (24). The reasons 
for this discrepancy remain unclear.
Although the expression of low-affinity Fc receptors, including 
CD32, on CD4+ T cells remains controversial (25, 26), resting CD4+ 
T cells express low frequencies of CD32, whereas CD32 expression 
increases upon T cell activation (27–29, 40). We found that expres-
sion of CD32 is enriched within cells expressing markers routinely 
used to deplete activated cells when studying HIV latency (CD69, 
HLA-DR, and CD25) (7, 30–35). Activation levels of the donor sam-
ples used in the report by Descours et al. were not reported. There-
fore, it remains unclear whether the lower viral outgrowth from 
CD32-depleted CD4+ T cells reported by Descours et al. reflects out-
comes associated with large disparities in baseline T cell activation 
between donors.
Immunoprofiling of CD32+ CD4+ T cells in blood and tissues of 
humans and RMs shows that these cells exhibit an activated and 
differentiated phenotype, making it unlikely that they are enriched 
with HIV latently infected cells. We were also unable to detect dif-
ferences in the frequencies of CD32+ CD4+ T cells between HIV- 
infected individuals (viremic and ART-suppressed) and healthy 
donors, otherwise expected if CD32a was a preferential biomarker 
for HIV-1 infection in CD4+ T cells (irrespective of latent or active 
infection). It was of interest to detect enrichment of markers consistent 
with TH2 cells (blood and tissue) and TH17 cells (tissue) within 
CD32+ CD4+ T cells. These phenotypes have been associated with 
HIV persistence and enriched replication capacity in vitro and ex vivo 
(41–45). It is important to consider, however, that the enrichment 
within the TH17 observed in tonsils, but not in peripheral blood, 
may be due solely to the rarity of this subset in circulation com-
pared to lymphoid tissue.
Our in vitro analyses show a direct link between CD32+ expres-
sion and productive HIV infection. Although HIV-infected CD32+ 
CD4+ T cells are more activated than HIV-infected CD32− CD4+ 
T cells, not all infected cells expressing HIV proteins were CD32+. 
Our data do not exclude the possibility that CD32+ cells are also 
preferentially infected. This possibility is very likely because CD32+ 
cells are more activated. However, these possibilities separately or 
jointly would not significantly affect our conclusion that a portion 
of cells actively transcribing HIV are also expressing CD32.
Consistent with the notion that CD32+ CD4+ T cells are enriched 
with transcriptionally active infection, cell-associated HIV RNA 
load was mostly closely associated with the activation and the ex-
pression of CD32 on CD69+ cells in both total and resting CD4+ 
T cells in the periphery. In addition, our RNA FISH experiments 
showing the coexpression of CD32a and HIV RNA in lymph tissue 
directly support the interpretation that CD32a is more likely to be 
associated with transcriptionally active rather than latent infection.
The role of CD32, if any, in determining the enrichment of HIV 
expression remains unknown. FcRII receptors play critical roles in 
shaping different immunological outcomes and direct antibody func-
tionality (46). FcRIIa and FcRIIc are activating receptors, where-
as FcRIIb is an inhibitory receptor (46). It remains unclear which 
functions are mediated by the immunomodulatory CD32 receptors 
on CD4+ T cells with regard to HIV infection, expression, and immune 
evasion, especially if their expression is triggered by T cell receptor–
mediated T cell activation.
The similarity of the extracellular domains of CD32a (FcRIIa), 
CD32b (FcRIIb), and CD32c (FcRIIc) does not allow us to differ-
entiate between the three receptors by flow cytometry because there 
are no available antibodies that can distinguish among them, and 
the available CD32a-specific antibody showed very low resolution 
(47). However, our RNA FISH data in LNs were generated using a 
CD32a-specific probe. Our data were primarily obtained from blood, 
LN tissues, and tonsils; thus, the need to analyze the role of CD32a 
expression to HIV persistence in additional tissues (such as gut- 
associated lymphoid tissues) after ART remains. The concordance 
of our data with SIV-infected macaques showing a relationship be-
tween CD32 and activation and the lack of enrichment of SIV DNA 
in sorted CD32+ CD4+ T cells raise the possibility that the RM model 
may be useful in greater tissue-centered analysis, as well as in testing 
strategies aimed at directly targeting CD32+ T cells. Last, our data 
describe cross-sectional groups in chronically infected adults, thereby 
the need to also analyze longitudinal changes, acute infection, and 
pediatric cohorts not addressed by our report.
In summary, our results show that CD32+ CD4+ T cells exhibit a 
distinct activation profile for transcriptionally active HIV. Although 
CD32 may provide a novel tool to better understand persistent HIV 
expression after ART, our data also stress the remaining need to find 
reliable and specific HIV latency biomarkers in resting CD4+ T cells 
for the development of effective targeting methods toward HIV 
eradication.
MATERIALS AND METHODS
Study design
This study was performed on fresh and frozen PBMCs, and ton-
sils from HIV−, HIV+-treated, and HIV+ viremic individuals (a total 
of 76 study participants; tables S1 and S3). PBMCs from HIV- infected 
viremic and ART-treated individuals were obtained from Wistar, The 
Centre for Research in Infectious Diseases (CIENI) of the National 
Institute of Respiratory Diseases (INER), and the Vall d’Hebrón 
Hospital. Tonsil samples were obtained from INER-CIENI. Healthy 
HIV− PBMC samples were obtained from Wistar and the University of 
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Pennsylvania Human Immunology Core. Additional PBMCs from 
HIV-infected donors were obtained from the University of Toronto. 
Written informed consent was provided by all patients, and the pro-
tocols used were approved by the Comité d’Ètica d’Investigació Clínica 
[Institutional Review Board (IRB) numbers 270/2015 and 196/2015], 
the INER-CIENI Ethics Committee, the Federal Commission for 
the Protection against Sanitary Risk (COFEPRIS; IRB number B03-16), 
and the IRBs of the University of Pennsylvania and Wistar (#2110176). 
Primary data are shown in table S4.
Animal studies
Five male RMs (Macaca mulatta), housed at the Yerkes National 
Primate Research Center (Atlanta, GA), were included in this study. 
All procedures are approved by the Emory University Institutional 
Animal Care and Use Committee, and animal care facilities are 
accredited by the U.S. Department of Agriculture and the Associa-
tion for Assessment and Accreditation of Laboratory Animal Care 
International.
Ex vivo infection kinetics of unstimulated PBMCs
PBMC samples from three healthy donors were used for these ex-
periments. Briefly, frozen PBMCs were thawed and incubated over-
night in R10 supplemented with streptomycin (100 g/ml), penicillin 
(100 U/ml), and interleukin-2 (IL-2; 40 U/ml). On the next day, one 
million PBMCs were infected with 350,000 TCID50 (50% tissue cul-
ture infectious dose) of NL4-3 viral strain for 4 hours at 37°C and 
5% CO2. After the initial infection, the cells were thoroughly washed 
and cultured in 96-well plates in R10 plus IL-2 (100 U/ml) for an 
additional 6 days to expand the initial viral infection. To focus our 
analysis on transcriptionally active HIV-infected cells, we performed 
the RNA FISH–flow assay at days 3, 4, 5, and 6, as previously described 
(48). For HIV RNA detection, we used target-specific Alexa Fluor 
647–labeled probes that contain a set of 50 probes spanning the whole 
Gag-Pol HIV mRNA sequence (bases 1165 to 4402; reference HXB2). 
We include antibodies for surface markers CD4 (BV510; BioLegend), 
CD3 [phycoerythrin (PE)–Cy5; BioLegend], CD32 (PE-Cy7; BioLegend), 
HLA-DR (Pe-Dazzle 594; BioLegend), and PD-1 (BV605; BD). The 
intracellular expression of the viral Gag p24 viral protein was detected 
with a PE–anti-p24 antibody (clone KC57 RD1; Beckman Coulter). A 
violet viability dye for flow cytometry (LIVE/DEAD Fixable Violet Dead 
Cell Stain Kit, Invitrogen) was included in all experiments to deter-
mine the cell viability. All samples were run on an LSRFortessa four- 
laser flow cytometer (Becton Dickinson) and analyzed with FlowJo 
v10 software (Tree Star).
CD32 expression after in vitro infection of activated  
CD4+ T cells
PBMCs were isolated from peripheral blood obtained via phlebotomy 
from HIV-1–negative donors per an active, approved University of 
Utah IRB protocol (#67637; principal investigator, A. M. Spivak). 
Total CD4+ T cells were purified via negative magnetic bead selec-
tion using a total CD4+ T cell–negative isolation kit (STEMCELL) 
according to the manufacturer’s instructions. CD4+ T cells were 
cultured in an RPMI 1640–based media supplemented with IL-2 
(30 IU/ml) and activated in vitro for 72 hours via exposure to anti-
bodies to CD3 and CD28 conjugated to magnetic beads (Invitrogen). 
Activated CD4+ T cells subsequently underwent spin infection with 
an HIV-1NL4–3 viral strain pseudotyped with green fluorescent pro-
tein in place of env (multiplicity of infection of about 1.0 using a titer 
measured in SupT1 cells) at 1200g for 2 hours at 37°C. CD4+ T cells were 
stained with the following fluorophore-conjugated antibodies be-
fore flow cytometry acquisition: CD3 (PE-Cy7; BioLegend), CD4 (al-
lophycocyanin; Life Technologies), CD32 (PE; Fun-2 clone; BioLegend), 
CD14 [Brilliant Violet (BV) 421; BioLegend], and HLA-DR (BV 605; BD 
Biosciences). Flow cytometry was performed at 0, 24, 48, and 72 hours 
relative to CD4+ T cell isolation, as well as 0, 24, and 48 hours after NL4-3 
infection. Flow cytometry acquisition was performed on a BD FACSCanto 
II instrument, and analysis was performed using FlowJo v10 software.
Ex vivo infection of cervical tissue
Human cervical tissue was obtained from healthy women undergoing 
hysterectomy for benign indication at University Hospital Germans 
Trias i Pujol (HUGTP; Badalona, Spain). Informed written consent 
was obtained from all participants, and the study protocols (IRB pro-
tocol number PI-17-159) and questionnaires were approved by the 
HUGTP Clinical Research Ethics Committee. Tissue was processed 
within 12 hours after surgery, and 8-mm3 blocks of mucosal epithelium 
with the underlying stroma were dissected as previously described 
(49). Eight blocks of tissue per condition were placed in RPMI 1640 
supplemented with 20% fetal bovine serum (R20) in a 12-well plate 
and infected with 7200 TCID50 of the viral stock HIV-1Bal or medium 
in control wells. For each experimental condition, duplicates were 
performed. After 2 hours of incubation at 37°C, tissue blocks were 
washed three times with 3 ml of phosphate-buffered saline in 6-well 
plates and placed back in a 12-well plate at eight blocks per well in 
1 ml of R20. Infected cervical tissue blocks were cultured for addi-
tional 12 days, with a change of medium every 3 days. Tissue diges-
tion with collagenase IV (Invitrogen) and manual dissociation were 
immediately carried out as previously described (49, 50). Cells were 
incubated with Aqua viability dye to distinguish dead cells and with 
CD45-AF700, CD19-V500, CD3-PerCP, CD4-BV605, CD8-APC, 
CD14-APC-H7, CD32PE-Cy7, and HLA-DR–BV421 (all from BD 
Biosciences). After surface staining, cells were intracellularly stained 
with KC57-PE antibody (Beckman Coulter) to determine p24 ex-
pression. All the events were acquired using a BD FACSAria Cell 
Sorter and analyzed [Flow Cytometry Platform, Germans Trias i Pujol 
Health Science Research Institute (IGTP)] with FlowJo vX.0.7 soft-
ware (Tree Star). Gating strategy consisted of a lymphocyte gate based 
on forward scatter versus side scatter, followed by doublet exclu-
sion, dead and CD19+ cells exclusion, and a CD3+ T cell gate from 
where the different gates shown were quantified.
RNA in situ hybridization in LNs
Paraffin-embedded LN samples from four viremic and two aviremic 
ART-treated HIV-infected patients and a healthy donor were ob-
tained from the Anatomical Pathology Department of the Hospital 
Universitari Vall d’Hebron (Barcelona, Spain). Written informed 
consent was provided by all of the patients who participated in this 
study, and the protocols used were approved by the Comité d’Ètica 
d’Investigació Clínica (IRB number 196–2015) of the Hospital Uni-
versitari Vall d’Hebron (Barcelona, Spain). For detection of RNA in 
paraffin-embedded samples, the ultrasensitive RNA detection assay 
ViewRNA ISH Tissue 2-Plex Evaluation Kit (eBiosciences) was used. 
Two high-sensitivity target-specific sets were used: one set of 50 probes 
spanning the whole Gag-Pol HIV mRNA sequence (bases 1165 to 
4402; reference HXB2) and another set of probes designed specifically 
to hybridize to human CD32a (bases 1046 to 2370; cat. no. VA6-
3171678). LN sections of 6 m were mounted on Superfrost Plus 
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microscope slides (Fisher Scientific). The assay was performed as 
previously described (48). Briefly, samples were deparaffinized with 
xylene and dehydrated with decreasing concentrations of ethanol. 
Section pretreatments were performed by heat-induced epitope re-
trieval and protease digestion. Next, probe hybridization was carried 
out by incubation of probes 2 hours at 40°C, and after that, samples 
were stored overnight in storage buffer (eBiosciences). Finally, signal 
amplification was performed by sequential incubation with pre-
amplifiers, amplifiers, and substrates. To counterstain slides, 4′,6- 
diamidino-2-phenylindole staining was performed.
Confocal microscopy and quantification of in situ 
hybridization LN samples
Samples were imaged on an Olympus Spectral Confocal Micro-
scope FV1000 using a 20× and 40× phase objective and sequential 
mode to separately capture the fluorescence from the different fluoro-
chromes at an image resolution of 800 × 800 pixels. Single HIV-1 
RNA–, single CD32a RNA–, or double HIV-1 RNA/CD32a RNA–
positive cells were determined by visual examination of 23 to 114 
B cell follicles per sample. Finally, MFI of HIV-1 RNA–positive cells 
and CD32a was measured in 10 to 15 B cell follicles using the ImageJ 
software.
Statistical analyses
Data were analyzed using Prism 6.0 and 7.0 (GraphPad Software). 
Nonparametric Mann-Whitney U tests, Wilcoxon rank tests, Spearman 
correlations, and Friedman tests were used, correcting for multiple 
comparisons with Dunnett’s posttest. PCA and hierarchical clustering 
were performed using R-Studio.
Please refer to the Supplementary Materials for details on anti-
bodies and staining protocols used to phenotype and sort CD32+ 
CD4+ T cells from human blood and tissue samples, as well as from 
RM tissues. In addition, the Supplementary Materials contain the 
details of the qPCR protocols used to measure HIV DNA loads, SIV 
DNA loads, and cell-associated HIV RNA loads.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/10/437/eaar6759/DC1
Materials and Methods
Fig. S1. Representative example of the gating strategy used for analyses in Fig.  1.
Fig. S2. Percentage of cells expressing the activation markers HLA-DR, CD69, or CD25 on total 
CD4+ T cells, CD32+ CD4+ T cells, and CD32− CD4+ T cells.
Fig. S3. Phenotyping of CD32+ CD4+ cells from peripheral blood.
Fig. S4. Phenotyping of CD32+ CD4+ cells from tonsils.
Fig. S5. CD4+ CD32+ T cells in the LN of ART-suppressed, SIV-infected RMs are enriched in 
activation markers but not in SIV DNA.
Fig. S6. Lack of correlations between frequency of CD32+ of resting CD4+ T cells and HIV DNA 
and RNA loads.
Fig. S7. Correlations between frequency of CD32− CD4+ T cells and HIV DNA and RNA loads.
Fig. S8. Different HIV RNA and CD32a RNA pattern expression in LN samples from HIV-infected 
patients.
Table S1. Clinical data of patients included in Figs.  1 and 5.
Table S2. DNA quantity and number of sorted cells examined in Fig.  5C.
Table S3. Clinical data of patients included in Figs.  2,  3, and 6.
Table S4. Primary data.
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 cells is unlikely to hit the HIV latent reservoir.+suggest that targeting CD32
 cells. Their results−indicating active HIV transcription. In contrast, the majority of HIV DNA resided in CD32
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